Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia

International Journal of Clinical Practice
M ObradovicM Kos


The aim of the present analysis was to evaluate the cost-effectiveness of alternative treatments for outpatients with chronic schizophrenia from the healthcare payer's perspective. Decision analysis was used to evaluate the cost-effectiveness of the following antipsychotic drugs: amisulpride, aripiprazole, haloperidol (oral formulation), haloperidol (depot formulation), olanzapine, quetiapine, risperidone (oral formulation), risperidone (depot formulation) and ziprazidone. Clinical and economic outcomes were modelled over 1-year time horizon. Effectiveness was measured as a percentage of patients in remission. Clinical parameters used in the model included compliance rates, rehospitalisation rates for compliant and non-compliant patients, duration and frequency of hospitalisation, and adverse event rates. One-way sensitivity analysis was performed to test the robustness of the model. The most effective treatment was treatment with olanzapine where 64.1% of patients remained in remission. The least effective treatment was treatment with quetiapine where 32.7% of patients remained in remission. Overall costs ranged from 3,726.78 Euro for haloperidol to 8,157.03 Euro for risperidone in depot formulation. Inpatient costs represente...Continue Reading


Jan 1, 1995·Schizophrenia Bulletin·P J Weiden, M Olfson
Jul 1, 1994·Medical Decision Making : an International Journal of the Society for Medical Decision Making·S B Cantor
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·H LooO Fleurot
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P V TranC M Beasley
Feb 2, 2000·Psychiatric Services : a Journal of the American Psychiatric Association·M OlfsonP J Weiden
Sep 19, 2000·International Clinical Psychopharmacology·S H HamiltonA Breier
Jan 5, 2002·The American Journal of Psychiatry·Christian R DolderDilip V Jeste
Jan 5, 2002·The New England Journal of Medicine·John G CsernanskyUNKNOWN Risperidone-USA-79 Study Group
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel SechterUNKNOWN Amisulpride Study Group
Dec 26, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Elliot M GoldnerJulian M Somers
Dec 31, 2002·Archives of Medical Research·Cynthia S PalmerDennis A Revicki
Apr 30, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Joseph MenzinJohn R Lloyd
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Aug 2, 2003·Schizophrenia Research·Rahul GangulyBradley C Martin
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Nov 11, 2003·Current Medical Research and Opinion·Ibrahim S Al-ZakwaniTara R Cockerham
Nov 19, 2003·Journal of Clinical Psychopharmacology·Charles M BeasleyUNKNOWN Olanzapine Relapse Prevention Study Group
Nov 25, 2003·The Journal of Clinical Psychiatry·Teresa A PigottUNKNOWN Aripiprazole Study Group
Jan 15, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·P Joseph GibsonJanet L Ramsey
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Stephen AlmondTraolach Brugha
Apr 13, 2004·International Clinical Psychopharmacology·Ann MortimerUNKNOWN SOLIANOL Sudy Group
Apr 21, 2004·The Journal of Clinical Psychiatry·Esperanza DiazScott W Woods
Jun 23, 2004·Journal of Clinical Psychopharmacology·John M Davis, Nancy Chen
Jul 29, 2004·Schizophrenia Bulletin·Marcia ValensteinThomas Stavenger
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Peter J WeidenJulie Locklear
Nov 4, 2004·CNS Drugs·Kate McKeage, Greg L Plosker
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Feb 24, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Dan CooperJean-Pierre Grégoire
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·B D ByromA T Kilpatrick

❮ Previous
Next ❯


Sep 6, 2013·Journal of Medical Economics·Thomas R Einarson, Michiel E H Hemels
Sep 29, 2015·Journal of Medical Economics·Thomas R EinarsonBasil G Bereza
May 17, 2011·Cost Effectiveness and Resource Allocation : C/E·Pudtan PhanthunaneMelanie Bertram
Dec 23, 2011·Advances in Urology·Erik JohnsenHugo A Jørgensen
Jul 12, 2016·Cost Effectiveness and Resource Allocation : C/E·Neha RaykarDan Chisholm
Jun 11, 2011·Journal of the American Psychiatric Nurses Association·Michael J Rice
Feb 26, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Birgitta von SchéeleAnita Patel
Aug 23, 2019·Journal of Clinical Pharmacy and Therapeutics·Iara Carolina Barbosa HenriquePatricia Melo Aguiar
Aug 2, 2017·Journal of Medical Economics·Thomas R EinarsonPieter J T Dries
Mar 8, 2020·PharmacoEconomics·Huajie JinSarah Byford
Aug 22, 2018·Journal of Market Access & Health Policy·Junwen ZhouMondher Toumi
Apr 9, 2009·Cost Effectiveness and Resource Allocation : C/E·Nicolas M FuriakSteven D Culler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here